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IMPORTANCE Disability secondary to skin conditions is substantial worldwide. The Global
Burden of Disease Study 2013 includes estimates of global morbidity andmortality due to
skin diseases.
OBJECTIVE Tomeasure the burden of skin diseases worldwide.
DATA SOURCES For nonfatal estimates, data were found by literature search using PubMed
and Google Scholar in English and Spanish for years 1980 through 2013 and by accessing
administrative data on hospital inpatient and outpatient episodes. Data for fatal estimates
were based on vital registration and verbal autopsy data.
STUDY SELECTION Skin disease data were extracted frommore than 4000 sources including
systematic reviews, surveys, population-based disease registries, hospital inpatient data,
outpatient data, cohort studies, and autopsy data. Data metrics included incidence,
prevalence, remission, duration, severity, deaths, andmortality risk.
DATA EXTRACTION AND SYNTHESIS Data were extracted by age, time period, case definitions,
and other study characteristics. Data points were modeled with Bayesian meta-regression to
generate estimates of morbidity andmortality metrics for skin diseases. All estimates were
made with 95% uncertainty intervals.
MAIN OUTCOMES ANDMEASURES Disability-adjusted life years (DALYs), years livedwith
disability, and years of life lost from 15 skin conditions in 188 countries.
RESULTS Skin conditions contributed 1.79% to the global burden of disease measured in
DALYs from 306 diseases and injuries in 2013. Individual skin diseases varied in size from
0.38% of total burden for dermatitis (atopic, contact, and seborrheic dermatitis), 0.29% for
acne vulgaris, 0.19% for psoriasis, 0.19% for urticaria, 0.16% for viral skin diseases, 0.15% for
fungal skin diseases, 0.07% for scabies, 0.06% for malignant skin melanoma, 0.05% for
pyoderma, 0.04% for cellulitis, 0.03% for keratinocyte carcinoma, 0.03% for decubitus ulcer,
and 0.01% for alopecia areata. All other skin and subcutaneous diseases composed 0.12% of
total DALYs.
CONCLUSIONS AND RELEVANCE Skin and subcutaneous diseases were the 18th leading cause
of global DALYs in Global Burden of Disease 2013. Excludingmortality, skin diseases were the
fourth leading cause of disability worldwide.
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G lobal disability and mortality due to skin disease hasbeen investigated by the Global Burden of Disease(GBD) 2013 Study. The GBD is a collaboration of more
than 1000 experts worldwide, aiming to create a systematic,
quantified, and internally consistent source of health
information.1 Based at the Institute for Health Metrics and
Evaluation and fundedby theBill andMelindaGates Founda-
tion, GBD 2013 provides disability and mortality metrics for
diseases, injuries, and risk factors stratified by age, sex, loca-
tion, and time.2,3 Disease burden was estimated using the
metric ofdisability-adjusted life year (DALY),which is the sum
of years of life lost to a disease (YLLs) plus years lived with
disability (YLDs). One DALY is equivalent to 1 year of healthy
life lost.4(pp6-7) This measurement unit allows for cross-
comparisonofdiversedisease states.Thegoal ofGBD is topro-
duce thehighest-qualityepidemiologicdatabyensuring trans-
parentanalyticstrategies that includeuncertaintydistributions,
promote internal consistency,andallowiterative revisionsover
time. Each GBD iteration incorporates new studies and im-
proved methodology, creating a “living” database to inform
clinical, research-oriented, andpolicy-makingdecisions. This
rollingdesignof thedata set allows for theadditionofnewdata
sources and improvements to the methods of estimation.
Global Burden of Disease 2013 made estimates for 306 dis-
easesand injuries in 188countries.AsGBDresearchersandcol-
laborators, we present results for 15 dermatologic conditions.
Methods
The analyses were carried out by the team members of the
Institute ofHealthMetrics and international skin expertswith
an interest in dermatoepidemiology. The following skin con-
ditions were selected based on available data, standardized
disease definitions, andprevalence: dermatitis (including the
common varieties of eczema: atopic, seborrheic, and contact
dermatitis), psoriasis, cellulitis, pyoderma, scabies, fungal skin
diseases,viral skindiseases, acnevulgaris, alopeciaareata,pru-
ritus,urticaria,decubitusulcer,malignant skinmelanoma,and
keratinocytecarcinoma(includingbasalandsquamouscell car-
cinomas). An additional category, “other skin and subcutane-
ous diseases,” encompasses the remainder of miscellaneous
skin conditions.5 InternationalClassificationofDiseases,Ninth
Revision (ICD-9) and ICD-10 codeswereused todefine eachof
the 15 skin disease categories (eTable 1 in the Supplement).
The initial step in theGBDestimation strategywas a thor-
ough investigation of the world literature using PubMed and
Google Scholar for data on the incidence, prevalence, remis-
sion, duration, severity, andmortality risk (only applicable for
selected skindiseases) of the 15 skin conditions.Datawere ex-
tracted by age, time period, and with information defining
uncertainty (standarderror, confidence interval, ornumerator/
denominator). Searcheswereperformed inEnglish andSpan-
ish languages for the years 1980 through 2013. Data were ex-
tracted from more than 4000 sources including systematic
reviews, surveys, population-based disease registries, hospi-
tal inpatient data, outpatient data, and cohort studies. Most
incidence data for certain skin diseases were obtained from 3
medical record sources: (1) inpatient data from Europe, Latin
America, and the United States, (2) outpatient data predomi-
nantly from the United States, and (3) in the case of basal cell
and squamous cell carcinoma of the skin, registry datawhere
it included keratinocyte carcinoma, for example, Northern
IrelandCancerRegistry, 2010 (see eTable 2 in the Supplement
for all GBD 2013 skin disease data sources).
Datapoints fromtheaforementioned literaturesearchwere
analyzed in a Bayesian meta-regression modeling tool,
DisMod-MR 2.0, to yield prevalence estimates that are con-
sistentwith theotheravailableepidemiologicalparameters for
eachof the skin conditions.All estimateswere generatedwith
1000 draws from the posterior distribution of the quantity of
interest, which allows for generation of 95% uncertainty
intervals. Compared with the previous GBD 2010 study,
DisMod-MRwas recoded andoptimized to runup to 50 times
faster and shifted from a negative binomial to an offset log-
normal model.6
The literature search for GBD 2013 compared with GBD
2010 doubled the data set for psoriasis with an additional 30
prevalence and 5 incidence studies. Psoriasis was also mod-
eled with a smaller remission assumption (0.05-0.15 remit-
ted cases per case per year), better reflecting a chronic dis-
ease pattern. Of note, the GBD definition of remission is the
rate at which cases stop fulfilling the case definition, that is,
cure. For cellulitis, 13 191 incidence data points from both in-
patientandoutpatient sampleswereadded.Noadditionaldata
sourceswere added for pyoderma in GBD 2013. However, du-
ration of disease was decreased from approximately 1 year in
GBD 2010 to between 2 weeks for treated disease to 4 weeks
for untreated disease in GBD 2013. For fungal skin diseases,
prevalencewasestimatedseparately for tineacapitisand“other
fungal skindiseases.” Similarly, prevalences of viralwarts and
molluscum contagiosum were modeled separately and then
summarized as “viral skin diseases.” In GBD 2010, studies for
“itch” were used as prevalence of pruritus, which inaccu-
rately included cases of pruritic skin and nonskin conditions.
Comparatively, GBD 2013 included only outpatient data from
Norwayand theUnitedStates and several datapoints fromthe
literature of patients with a diagnosis of pruritus (excluding
known causes of itch).While no additional data sourceswere
Key Points
Question What is the burden of skin disease worldwide?
Findings In this observational study, skin diseases contributed
1.79% to the global burden of disease measured in
disability-adjusted life years (DALYs). Skin diseases arranged in
order of decreasing global DALYs are as follows: dermatitis (atopic,
contact, seborrheic), acne vulgaris, urticaria, psoriasis, viral skin
diseases, fungal skin diseases, scabies, melanoma, pyoderma,
cellulitis, keratinocyte carcinoma, decubitus ulcer, and alopecia
areata.
Meaning Skin diseases remain a major cause of disability
worldwide. An objective measure of burden, such as the DALY,
allows for comparison of diverse diseases across geography and
time.
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added, acne vulgaris modeling in GBD 2013 no longer as-
sumes that reported data include asymptomatic cases be-
causemost data pointswere basedonexamination and there-
forewould reflect symptomatic cases.Foralopeciaareata,GBD
2013applied lowerestimates fromthe largestdata source (out-
patient data from the United States). No new data sources for
urticaria were added; however, similarly to the case for acne
vulgaris, GBD 2013 urticaria data points reflect solely symp-
tomatic cases. For decubitus ulcer, input datawere incidence
fromhospital admissionandoutpatientdata. InGBD2010, im-
plausible duration estimates led to an overestimate of preva-
lence, which has been corrected in GBD 2013. Global Burden
ofDisease 2013 set bounds on the remission rate from0.5 to 6
corresponding to duration range of 2 months to 2 years.
Years lived with disability due to skin cancers were esti-
mated for 4 different sequelae: (1) diagnosis and treatment,
(2) remission, (3) metastatic disease, and (4) terminal dis-
ease. The survival timeframewasextended from5 to 10years.
The duration of diagnosis and treatment for keratinocyte car-
cinoma was taken as the same as for melanoma from Neal
et al7 (duration until diagnosis plus 2 months for treatment).
AsdefinedbyNealetal,7durationuntildiagnosis includeddays
from first presentation in general practice (GP) to referral or
GP biopsy, days from referral to first seen in clinic, days from
first seen in clinic to biopsy/wide local excision for GP exci-
sions, and days from presentation to biopsy/wide local exci-
sionforGPexcisions.Durationof theremissionsequela isbased
on time until death or 5 years for survivorsminus duration of
theothersequelae.Durationofdisseminateddiseasewasbased
on Nolan et al8 for lethal keratinocyte skin cancers and on
Surveillance, Epidemiology, and End Results9 analysis of
median survival for patients with stage IV melanoma.
Prevalence estimates from the estimation strategy were
combined with disability weights to yield skin disease mor-
bidity, expressed in YLDs, for each age-sex-country-year
group. Disability weights, which range from 0 to 1 for each
condition, were derived from 4 population-based European
surveys (30 660 respondents) and the GBD 2010 disability
weight surveys (30 230 respondents) eliciting response to
the question “who is the healthier?” for randomly chosen
pairs of health states. Health states were presented with a
short lay description. For parsimony, a smaller number (235)
of health states were designed to cover the spectrum of dis-
ability across all 2337 disease sequelae. The most commonly
used health states for skin disease were 3 levels of severity of
disfigurement with or without itch and/or pain.10 The lay
descriptions for disfigurement assessed in the disability
weight surveys include psychological morbidity attributable
to each skin disease. The mild infectious disease health state
was also used for bacterial, fungal, and viral skin diseases.
See Table 1 for descriptions of health states used to generate
disability weights for skin diseases.
Deaths and YLLs were estimated for the following 6 skin
categories: malignant skin melanoma, keratinocyte carci-
noma,cellulitis,pyoderma,decubitusulcer, andother skinand
subcutaneous diseases. The Cause of Death EnsembleModel
(CODEm) toolwas used to producemortality estimates based
on data on causes of death from the extensive GBD collection
ofvital registrationandverbalautopsydata.11TheCODEmstrat-
egy uses a range of plausible models and predictive covari-
ates for each cause and chooses the best-performing models
to yield predictions for cause-specific death estimates with
uncertainty intervals.TheYLLs foreachage-sex-countrygroup
are the multiplication of death counts at the age at death by
remaining lifeexpectancy fromtheGBDstandard life table that
is applied equally to all countries andperiods.2Mortality from
the remaining skin conditions was assumed to be 0.
Morbidity (YLD)andmortality (YLL)estimateswereadded
for each age-country-sex group to yield DALYs, which are re-
ported as numbers, percent of total DALYs from all condi-
tions studied by GBD, and the DALY rate per 100000 per-
sons. Estimates were made for both sexes and 21 age groups
ranging from the first week of life to older than 80 years, as
well as age-standardized estimates. Age standardization was
applied based on the standard population structure of popu-
lation in 2010 through 2035 as estimated for GBD 2013 based
on themost recentWorld Population Prospects by the United
NationsPopulationDivision.11,12 Finally, theGBDanalysiswas
computed for 188 countries grouped into 21 GBD world
regions.13 The Global Burden of Disease Study has institu-
tional reviewboardapproval throughMarch25,2018, fromthe
University of Washington.
Table 1. Skin Disease Disfigurement Health States and DisabilityWeights
Disfigurement
Health State Description
Disability Weight Value
(95% CI)
Disfigurement, level 1 This person has a slight, visible physical deformity that others notice, which causes
some worry and discomfort.
0.011 (0.005-0.021)
Disfigurement, level 2 This person has a visible physical deformity that causes others to stare and comment.
As a result, the person is worried and has trouble sleeping and concentrating.
0.067 (0.044-0.096)
Disfigurement, level 3 This person has an obvious physical deformity that makes others uncomfortable, which
causes the person to avoid social contact, feel worried, sleep poorly, and think about suicide.
0.405 (0.275-0.546)
Disfigurement,
level 1 with itch/pain
This person has a slight, visible physical deformity that is sometimes sore or itchy.
Others notice the deformity, which causes some worry and discomfort.
0.027 (0.015-0.042)
Disfigurement,
level 2, with itch/pain
This person has a visible physical deformity that is sore and itchy. Other people stare
and comment, which causes the person to worry. The person has trouble sleeping and
concentrating.
0.188 (0.125-0.267)
Disfigurement,
level 3, with itch/pain
This person has an obvious physical deformity that is very painful and itchy. The physical
deformity makes others uncomfortable, which causes the person to avoid social contact,
feel worried, sleep poorly, and think about suicide.
0.576 (0.401-0.731)
Infectious disease,
acute episode, mild
This person has a low fever and mild discomfort, but no difficulty with daily activities. 0.006 (0.002-0.017)
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Results
Skin and subcutaneous diseaseswere responsible for 41.6mil-
lionDALYsand39.0millionYLDs in2013.Theage-standardized
percentchangeinDALYratefrom2005to2013was0.1%.Table2
lists age-standardizedDALYratesper 100000persons,percent
change inDALY rates from2005 to 2013, and all-ageDALYs for
the 14skinconditionsandtheother skinandsubcutaneousdis-
easescategory.ResultsarepresentedinorderofdecreasingDALY
rate.Dermatitis,whichincludesestimatesforatopic, seborrheic,
andcontactdermatitis, is responsible for the largest globalbur-
denofDALYsandYLDs.While cellulitis causesan intermediate
globalburdencomparedwith theotherskinconditions, it expe-
riencedthegreatestdecline from2005to2013andwas theonly
skin conditionwith a significant change. This changewas due
to a decrease in death estimates.
The age-stratified breakdown for the skin conditions is
shown in Figure 1. Due to age restrictions, estimates for pa-
tients younger than 1 year were only available for the follow-
ing conditions: cellulitis, pyoderma, scabies, and fungal and
viral skin diseases. In addition, the age categories of 1 to 4, 5
Figure 1. Age Distribution of Skin and Subcutaneous Disease Burden
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This figure shows disability-adjusted life year (DALY) rate per 100000 persons from 15 skin disease categories throughout the human life span.
Table 2. Age-Standardized Disability-Adjusted Life Year (DALY) Rates per 100000Persons, Percent Change in DALY Rate From 2005-2013,
and DALYs for the 15 Skin Conditions
Skin Condition
Age-Standardized DALY Rate
per 100 000 Persons
(95% UI)
Change in DALY Rate
2005-2013,
% (95% UI)
DALYs, Millions
(95% UI)
YLDs
(95% UI)
Dermatitis 128.7 (83.6 to 184.9) 0.1 (−0.4 to 0.6) 9.3 (6.0 to 13.3) 9.3 (6.0 to 13.3)
Acne vulgaris 96.7 (46.4 to 177.8) −0.5 (−6.5 to 7.7) 7.2 (3.4 to 13.2) 7.2 (3.4 to 13.2)
Urticaria 67.0 (43.2 to 95.5) 4.3 (−9.4 to 16.1) 4.7 (3.0 to 6.7) 4.7 (3.0 to 6.7)
Psoriasis 66.8 (46.0 to 93.6) −0.5 (−1.6 to 0.6) 4.7 (3.2 to 6.6) 4.7 (3.2 to 6.6)
Viral skin diseases 54.7 (33.3 to 85.0) −0.6 (−1.5 to 0.3) 4.0 (2.4 to 6.2) 4.0 (2.4 to 6.2)
Fungal skin diseases 54.0 (22.1 to 114.2) 1.0 (0.5 to 1.4) 3.8 (1.6 to 8.1) 3.8 (1.6 to 8.1)
Scabies 23.5 (13.3 to 37.3) −2.8 (−10.2 to 6.7) 1.7 (0.97 to 1.7) 1.7 (0.97 to 1.7)
Melanoma 23.2 (18.1 to 31.1) −6.1 (−13.0 to −0.8) 1.6 (1.2 to 2.1) 0.14 (0.092 to 0.22)
Pyoderma 16.6 (13.0 to 19.3) 6.4 (−7.2 to 21.3) 1.1 (0.89 to 1.3) 0.033 (0.012 to 0.072)
Cellulitis 15.5 (11.8 to 20.2) −13.2 (−21.1 to −1.7) 1.1 (0.81 to 1.4) 0.12 (0.079 to 0.17)
Keratinocyte carcinoma 12.9 (10.8 to 16.3) −6.2 (−10.7 to 0.0) 0.82 (0.68 to 1.0) 0.13 (0.082 to 0.19)
Decubitus ulcer 10.8 (9.1 to 12.7) −0.8 (−5.8 to 4.6) 0.66 (0.55 to 0.78) 0.28 (0.20 to 0.37)
Alopecia areata 4.2 (2.7 to 6.3) −0.1 (−2.9 to 2.7) 0.29 (0.19 to 0.43) 0.29 (0.19 to 0.43)
Pruritus 0.2 (0.1 to 0.3) 0.9 (−6.2 to 8.6) 0.011 (0.0051 to 0.020) 0.0011 (0.0051 to 0.0020)
Other skin and
subcutaneous diseases
44.2 (19.8 to 93.3) 0.4 (−0.7 to 1.6) 3.0 (1.4 to 6.2) 2.9 (1.3 to 6.1)
Abbreviations: UI, uncertainty interval; YLDs, years lived with disability.
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to 9, and 10 to 14 years had no DALY estimates for melanoma
or keratinocyte carcinoma. Dermatitis burden remains rela-
tively consistent throughout all age categories, in compari-
son with acne vulgaris, which causes the greatest burden be-
tween the first and third decades of life. Skin conditionswith
the greatest burden in younger ages also include infectious
causes, such as viral skin diseases (mostly viral warts), bacte-
rial skin diseases (pyoderma and cellulitis), and scabies. Bur-
den frompsoriasis, alopecia areata, urticaria, fungal skin dis-
eases, and decubitus ulcer is greater in older age categories.
Keratinocyte carcinoma andmelanoma burden increase over
thehumanage-span,withthegreatestDALYrates in thoseolder
than 75 years.
Melanoma causes the greatest burden in Australia, fol-
lowed by high-income North America, Western Europe, and
Central Europe (Figure 2). Similarly, keratinocyte carcinoma
causes the greatest burden in Australasia, the Caribbean,
Central Latin America, and tropical Latin America. Dermati-
tis burden follows a similar geographic predominance, with
a high DALY rate in central sub-Saharan Africa. Psoriasis
causes the greatest burden in Australasia, Western Europe,
high-income Asia-Pacific, and southern Latin America.
Burden from acne vulgaris is greatest in Western Europe,
high-income North America, and southern Latin America.
Central, western, and eastern sub-Saharan Africa, along
with Oceania, have the highest DALY rates from cellulitis.
Burden from urticaria is evenly distributed among
world regions. Decubitus ulcer has the greatest DALY rate
in Oceania.
Discussion
The importance of the skin disease global burden can be ap-
preciated by comparing the skin results presented here as
DALYs or YLDs with the 158 disease and injury categories at
level 3 of the GBD 2013 hierarchy.14,15 Comparing absolute
DALYs and/or YLDs, skin and subcutaneousdiseaseswere the
18th leadingcauseofglobalDALYsandthe fourth leadingcause
of nonfatal burden in GBD 2013. Burden from skin diseases
(41.0 million DALYs) ranked directly behind iron deficiency
anemia (43.7millionDALYs), tuberculosis (49.8millionDALYs),
and sense organ diseases (54.4millionDALYs). As a reference
point, the leading cause of global DALYs over the past decade
has been ischemic heart disease, responsible for 150.2 mil-
lionall-ageDALYs in2013.Excludingmortality,YLDs fromskin
diseases (36.4million) are larger than those caused by diabe-
tes mellitus (29.5 million) and migraines (28.9 million).
A commitment to accurate, transparent, and frequently
updatedmetrics of disease burden has the potential to affect
diverse levels of health care and further the role of dermatol-
ogy in global health. The objectives of GBD are aligned with
efforts of international organizations suchas theWorldHealth
Organization and theUnitedNations.16 Anexample of derma-
tology research and leadership as a global collaboration is the
International Federation of Dermatology Clinical Trials
Network.17 This organization promotes the development of
standardizedand transparent clinical trials indermatology, in-
dependentof industry.Dermatologists havean important role
Figure 2. Regional Distribution of Skin and Subcutaneous Disease Burden
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This figure shows disability-adjusted life year (DALY) rate per 100000 persons from 15 skin disease categories throughout 21 world regions.
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in this global health landscape.Not onlydo skindiseases cause
substantial pain, disfigurement, and psychological and finan-
cial morbidity, but dermatologic findings are often the initial
manifestation of systemic disease.18 Global Burden of Disease
metrics and patterns have the potential to affect clinical trials
on a global scale.
Dermatologicalresearch,education,clinicalapplication,and
localandnationalhealthsupportarecritical tenetsofdermatolo-
gy’s role on the global health platform.19,20 As an example, the
InternationalFoundationforDermatology isan internationalor-
ganization founded in 1987 that aims to improve dermatologic
careinunderservedareasof low-andmiddle-incomecountries.21
Aparticularfocushasbeenkeratinocytecarcinomaintropicalre-
gions.GlobalBurdenofDisease2013demonstrateshighincidence
andburdenofkeratinocytecarcinoma insouthernsub-Saharan
Africa(includingBotswana,Lesotho,Namibia,SouthAfrica,Swa-
ziland,andZimbabwe),which ishypothesizedtobeparticularly
duetomortality fromkeratinocytecarcinomareflectingpoorac-
cess tohealthcareandhighprevalenceofhuman immunodefi-
ciencyvirus infectionandalbinism.22,23TheInternationalFoun-
dation for Dermatology has identified a particular vulnerable
group in the tropics,personswithalbinism(PWA),whoarepre-
disposed to premature skin cancer morbidity and mortality.24
Achievements from the PWA Working Group include skin
cancerprevention,education,andthedevelopmentofnovelsun-
screen products.
Afinalexampleof the impactofdiseaseburdenindermatol-
ogyistheCochraneCollaboration.Composedof53reviewgroups
andmembers across theworld, the organization conducts sys-
tematic reviews of randomized clinical trials for a diverse array
of health care topics and interventions.25 The Cochrane Skin
Groupfocusesonvariousaspectsofskindiseasediagnosis,man-
agement,andpreventionandspecifically includesburdenofdis-
ease inpriority setting for newreview topics.26 For example, as
demonstratedbyGBD2013, thegreatestglobalburdenfromskin
disease is attributed to dermatitis. Of the skin diseases studied
byGBD2013,dermatitishadthegreatest representationinCoch-
ranesystematicreviewsandprotocols.27Otherfactorsforreview
prioritization include,butarenot limitedto,knowledgegap,ca-
pacitybuilding,opportunityforscientificinnovation,equity,exis-
tenceofothersystematic reviews,availabilityofpublic funding,
health importance, and cost-effectiveness.
Limitations
Global Burden of Disease has applied global efforts and
sophisticated statistical approaches to make best estimates
from raw data. As such, the study’s limitations include
sparse data for some global areas due in part to the use of
coding systems other than ICD in primary care that limited
skin disease data availability. Global Burden of Disease
methodology depends on statistical methods to generate
predictions for areas where direct prevalence estimates for a
particular disease are not available. For countries, years,
ages, and sexes without data, predictions are generated by
deriving information from data in nearby countries and
regions and, where available, predictive covariates. This ana-
lytical strategy has the limitation that it is based on assump-
tions informed by either current knowledge of disease risk
factors, country-level covariates, or, more commonly, geo-
graphical region averages. For most skin diseases, no
country-level covariates were used, as there is limited
knowledge about risk factors. Thus, predictions rely solely
on data for countries in the same region or superregion. In
addition, GBD estimates are inherently dependent on accu-
rate interpretation of ICD codes and case definitions used by
studies contributing data. With each iteration of GBD, dis-
ease classification methods become more standardized and
can become a guide to epidemiologists collecting empirical
data on preferred case definitions and study methods.
Conclusions
The GBD collaboration has recently emerged as the first non-
governmental organization to affect the global landscape of
healthmetrics.28,29 Patterns of disease burden can be used to
correlatewith disease pathogenesis.With theworldwide col-
laboration of experts; attention to diverse causes, risk fac-
tors,ages,andworldregions;andsophisticatedanalyticalmod-
eling tools, GBD 2013 has established a standardizedmethod
for globalhealthmetrics.This advancementhas important im-
plications for the field of public health and clinical medicine,
including dermatology, as it will aid research priority-setting
decisions and public policy efforts at local and national
levels.
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